BIOGENERICS
BioGenerics, Inc. operates as a biotechnology company. The company was incorporated in 2010 and is based in Redwood City, California.
BIOGENERICS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2010-01-01
Address:
Redwood City, California, United States
Country:
United States
Website Url:
http://www.biogenerics.net
Total Employee:
1+
Status:
Active
Total Funding:
4.66 M USD
Technology used in webpage:
Apache
Current Employees Featured
Founder
Official Site Inspections
http://www.biogenerics.net
- Host name: sh23046.ispgateway.de
- IP address: 92.205.49.78
- Location: Germany
- Latitude: 51.4476
- Longitude: 7.0122
- Timezone: Europe/Berlin
More informations about "BioGenerics"
BioGenerics - Crunchbase Company Profile & Funding
BioGenerics closed its last funding round on Jul 25, 2011 from a Debt Financing round. Who are BioGenerics 's competitors? Alternatives and possible competitors to BioGenerics may include TRELYS , BioVinc , and Certified …See details»
BioGenerics - Drug pipelines, Patents, Clinical trials - Synapse
Explore BioGenerics with its drug pipeline, therapeutic area, technology platform, 10 news.See details»
Biogenerics – Evolving Risks and Opportunities_M …
Dec 27, 2008 1. Biogenerics – Evolving Risks and Opportunities for Biopharmaceutical, Generic, and Contract Manufacturers Mark A. Staples, Ph.D. Consultant, Cambridge, MA 2008 BioPharma Outsourcing: Partnerships with …See details»
Biogenerics: potential benefits and obstacles - PubMed
Although the patents for several costly and successful biologics have expired or will expire in the near future, no biogenerics have yet been approved. The scientific difficulties of replicating …See details»
From Biologics to Biosimilars and Biobetters – Democratization of …
A biosimilar is a “biological product highly similar to the approved innovator product, with no clinically meaningful differences in safety, purity, and potency”.[1,2,3] Also known …See details»
What Is a Generic Biopharmaceutical? Biogeneric? Follow-on …
And biogenerics-related information organization and management — prerequisites for the development and dissemination of knowledge. This in turn drives perceptions that largely …See details»
Biogenerics: the hope and the hype: Trends in Biotechnology - Cell …
Jul 8, 2009 The US Congress is likely this year to create a clearly defined pathway for the development and regulatory approval of generic copies of ‘biological’ drugs* – drugs obtained …See details»
Biogenerics - Boston Oncology
Class-Leading Biogenerics. Boston Oncology maintains a diverse and extensive portfolio of best-in-class generic and biosimilar therapeutics—USFDA / EMA registered and licensed from world-renowned innovator …See details»
Betting on biogenerics | Nature Reviews Drug Discovery
Mar 1, 2004 Nature Reviews Drug Discovery - Betting on biogenerics. Perhaps the biggest single uncertainty surrounding the approval of biogeneric drugs is the global regulatory situation.See details»
Betting on biogenerics - Nature Biotechnology
The main obstacle is that biogenerics must clear many more regulatory hurdles than traditional small-molecule generics, and this situation is unlikely to change in the near future.See details»
Biogeneric Drugs Market Size, Trends and Forecast To 2032
Nov 18, 2024 COVID-19 Impact: Pandemic Induced Challenges As Supply Chain Disruptions Impact Biogenerics Production And Distribution. The COVID-19 pandemic has been …See details»
(PDF) Biogenerics or Biosimilars: An overview of the
Dec 5, 2011 According to estimation, biologic drugs worth more than $80 billion in global sales will lose patent protection by the year 2015, presenting a major opportunity for biogenerics. …See details»
Biogenerics: On Route to Regulatory Approval? - Patent - Mondaq
Mar 22, 2005 The generic drug market is now firmly established as a major part of the European pharmaceutical sector, with generics forming a significant proportion of off-patent drug sales, …See details»
Biogenerics: the hope and the hype - PubMed
Biogenerics: the hope and the hype. Biogenerics: the hope and the hype. Biogenerics: the hope and the hype Trends Biotechnol. 2009 Aug;27(8):443-4. doi: 10.1016/j.tibtech.2009.04.005. …See details»
Biogenerics: Are They Really Worth It? - SAGE Journals
All subjects Allied Health Cardiology & Cardiovascular Medicine Dentistry Emergency Medicine & Critical Care Endocrinology & Metabolism Environmental Science General Medicine Geriatrics …See details»
Betting on biogenerics - Nature
Organization,and requests by pharmaceutical companies for the rejection of the section for biological products because of all the potential ... of biogenerics is unlikely to be …See details»
Generics and Biosimilars: Barriers and Opportunities - Mayo Clinic ...
Oct 30, 2021 The affordability of prescription drugs continues to occupy a significant position in health policy debate, with most Americans believing that lowering their cost is a top health …See details»
'Biogenerics': the off-patent biotech products - PubMed
We propose the term off-patent biotechnological products (OPBPs) as an alternative to biogenerics when describing such products. It is questionable whether the majority of OPBPs …See details»
Iranian guidelines for ‘biogenerics’ - GaBi Online
Sep 5, 2014 FDO issued a guideline regarding the regulation of ‘biogeneric’ products in January 2014. The FDO guideline is an overarching guideline covering general considerations for …See details»
[PDF] What Is a Generic Biopharmaceutical ... - Semantic Scholar
MAY 2007 P art 1 of this three-article series considered various views, paradigms, and definitions of generic biopharmaceuticals (biogenerics), exploring some of the many diverse and …See details»